Wolfgang Miesbach: Discussing Immunological Challenges in Hemophilia at GTH 2026
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“A standout session at GTH was ‘The immunogenicity of therapeutic proteins in hemostasis – an overview’ by Sebastien Lacroix-Desmazes.
The talk clearly highlighted the immunological challenges in haemophilia — from classical FVIII inhibitors to gene therapy and anti-drug antibodies (ADAs) against newer engineered therapies.
One especially interesting point: FVIII-mimetic bispecific antibodies do not seem to share the same immunogenic profile
- Emicizumab։ ADA signal reported
- NXT007։ ADA signal also observed in early studies
- Mim8։ no ADA signal in the study presented
A likely reason is molecular design:
- Emicizumab is a humanized and highly engineered bispecific antibody; such optimization can improve function, but may also introduce non-self sequences or neoepitopes.
- NXT007, as a further optimized derivative, may retain or add immunogenic determinants.
- Mim8, with a more fully human design strategy, may reduce immune recognition
Take-home message:
Shared mechanism does not equal shared immunogenicity. Even when therapies target the same pathway, immune responses can differ because of humanization strategy, sequence design, and epitope architecture.”

Find more posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters
-
Jun 24, 2026, 13:43Brandon Michael Henry: Interpreting Complement Activation After AAV Gene Therapy
-
Jun 24, 2026, 13:37Heba Youssef: Heparin-Induced Thrombocytopenia – The Prothrombotic Emergency You Cannot Miss
-
Jun 24, 2026, 13:32Jecko Thachil: Understanding the Clinical Spectrum of Vitamin B12
-
Jun 24, 2026, 13:32Namrata Singh: Beyond Low Platelets – Understanding What Triggers ITP
-
Jun 24, 2026, 09:29Advancing Women’s Health Through Collaboration with Jean Hailes for Women’s Health – Stroke Foundation
-
Jun 24, 2026, 09:18The Lasting Immunological Footprint of VITT – JTH
-
Jun 24, 2026, 09:09Umberto Pensato: Dedicated Funding Pathways for Stroke Research in Italy
-
Jun 24, 2026, 09:00Danny Gaskin: BBTS 2026 and the Evolving Role of Transfusion in Maternity Care